News · 26 weeks59+250%
2026-04-192026-10-11
Mix2190d
- Insider9(43%)
- Other6(29%)
- SEC Filings3(14%)
- Earnings2(10%)
- Analyst1(5%)
Latest news
25 items- PRGlaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract SurgeryStudy Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority and Clinically Meaningful IOP Reduction vs. Cataract Surgery Alone iDose TR in Combination with Cataract Surgery Demonstrated Robust Mean IOP Reduction of 11.1 mmHg and Favorable Safety Profile Through 3 Months Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared t
- PRGlaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal DiseasesLicense agreement also grants Glaukos exclusive rights to the RevMod™ platform for the discovery and development of up to four additional next-generation biologics for various retinal diseases Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). T
- INSIDERSEC Form 4 filed by Glaukos Corporation4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in KeratoconusThree-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sight-threatening corneal disease that remains significantly undiagnos
- PRGlaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026. A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-99
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas sold $249,158 worth of shares (1,615 units at $154.28) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 70,818 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of KeratoconusNew Campaign Aims to Raise Awareness, Educate Patients and Families, and Promote Earlier Detection and Diagnosis Curry to Share His Personal Journey Living with Keratoconus to Empower Individuals to Prioritize Proactive Eye Care and Recognize the Importance of Early Detection Could it be KC? Campaign and Curry Partnership Underscore Glaukos’ Commitment to Addressing Keratoconus Underdiagnosis and Undertreatment Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas sold $243,204 worth of shares (1,457 units at $166.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 72,433 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas sold $2,483,104 worth of shares (13,744 units at $180.67), decreasing direct ownership by 16% to 73,890 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Kliman Gilbert H exercised 2,500 shares at a strike of $25.77 and sold $475,000 worth of shares (2,500 units at $190.00) (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos Announces Participation in Wells Fargo Healthcare ConferenceGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the
- INSIDERPRESIDENT & COO Gilliam Joseph E sold $10,784,659 worth of shares (60,000 units at $179.74) and exercised 60,000 shares at a strike of $52.94 (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. sold $3,602,600 worth of shares (20,000 units at $180.13) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $33.81 (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Wen Leana sold $88,006 worth of shares (525 units at $167.63), decreasing direct ownership by 2% to 21,092 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- SECGlaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - GLAUKOS Corp (0001192448) (Filer)
- SECSEC Form 10-Q filed by Glaukos Corporation10-Q - GLAUKOS Corp (0001192448) (Filer)
- SECGlaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - GLAUKOS Corp (0001192448) (Filer)
- PRGlaukos Announces Second Quarter 2026 Financial ResultsGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include: Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis. Glaucoma record net sales of $155.2 million in Q2 2026 increased 50% year-over-year. U.S. Glaucoma record net sales of $118.5 million in Q2 2026 increased 64% year-over-year. Gross margin of approximately 82% and non-GAAP gross margin of approxi
- ANALYSTUBS initiated coverage on GlaukosUBS initiated coverage of Glaukos with a rating of Neutral
- PRGlaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShuntGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment. The PRESERFLO MicroShunt is a novel, ab-externo glaucoma drainage device designed to lower intraocular pressure (IOP). Constructed from a proprietary, biocompatible material known as SIBS [poly(styrene-block-isobutylene-block-styrene)], the PRESERFLO MicroShunt is an 8.5
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,600,000 worth of shares (10,000 units at $160.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,550,000 worth of shares (10,000 units at $155.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,500,000 worth of shares (10,000 units at $150.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas sold $99,567 worth of shares (716 units at $139.06) as part of a pre-agreed trading plan, decreasing direct ownership by 0.81% to 87,634 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29Conference Call and Webcast Scheduled for 1:30 p.m. PTGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 29, 2026.A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (Internat
GKOS FAQ
7 questionsWhat does Glaukos Corporation do?
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure...Where does GKOS stock trade?
Glaukos Corporation (GKOS) is listed on NYSE.What sector and industry is GKOS in?
Glaukos Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Glaukos Corporation go public?
Glaukos Corporation (GKOS) completed its IPO in 2015.What are analysts saying about GKOS?
Glaukos Corporation has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral on 2026-07-28.What companies are similar to GKOS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare GKOS side-by-side with any of them on Quantisnow.How can I track GKOS on Quantisnow?
Quantisnow aggregates Glaukos Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GKOS to receive live email and push alerts on every new disclosure.